Non-invasive prenatal testing for fetal chromosome abnormalities: Review of clinical and ethical issues

Application of Clinical Genetics

Volumn 9, Issue , 2016, Pages 15-26

  Gekas, Jean ^a,b   Langlois, Sylvie ^c   Ravitsky, Vardit ^d   Audibert, François ^e   van den Berg, David Gradus ^a   Haidar, Hazar ^d   Rousseau, François ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Cell free fetal DNA; Down syndrome; Informed consent; Non invasive prenatal testing; Prenatal diagnosis; Reproductive autonomy

Indexed keywords

CASE CONTROL STUDY; CHROMOSOME ABERRATION; CLINICAL PRACTICE; CLINICAL RESEARCH; COHORT ANALYSIS; DNA SCREENING; EVIDENCE BASED MEDICINE; FETUS; GENOMICS; HEALTH PROGRAM; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; NON INVASIVE PROCEDURE; OBSERVATIONAL STUDY; PERFORMANCE; PRENATAL SCREENING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL ASPECT;

EID: 84958178191     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S85361     Document Type: Review

References (166)

1. Greydanus DE, Pratt HD. Syndromes and disorders associated with mental retardation. Indian J Pediatr. 2005;72(10):859–864.
2. Chitayat D, Langlois S, Wilson RD. Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can. 2011; 33(7):736–750.
3. Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update. 2009;15(1):139–151.
4. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;45(1):16–26.
5. Vanstone M, King C, de Vrijer B, Nisker J. Non-invasive prenatal testing: ethics and policy considerations. J Obstet Gynaecol Can. 2014; 36(6):515–526.
6. de Jong A, Maya I, van Lith JM. Prenatal screening: current practice, new developments, ethical challenges. Bioethics. 2015;29(1):1–8.
7. Dondorp W, de Wert G, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet. 2015;23(11):1592.
8. Lutgendorf MA, Stoll KA, Knutzen DM, Foglia LM. Noninvasive prenatal testing: limitations and unanswered questions. Genet Med. 2014;16(4):281–285.
9. Sehnert AJ, Rava RP, Bianchi DW. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369(22):2164–2165.
10. Ashwood ER, Palomaki GE. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369(22):2164.
11. Wright CF, Chitty LS. Cell-free fetal DNA and RNA in maternal blood: implications for safer antenatal testing. BMJ. 2009;339:b2451.
12. Schmitz D, Netzer C, Henn W. An offer you can’t refuse? Ethical implications of non-invasive prenatal diagnosis. Nat Rev Genet. 2009; 10(8):515.
13. Gekas J, Gagne G, Bujold E, et al. Comparison of different strategies in prenatal screening for Down’s syndrome: cost effectiveness analysis of computer simulation. BMJ. 2009;338:b138.
14. Druzin ML, Chervenak F, McCullough LB, Blatman RN, Neidich JA. Should all pregnant patients be offered prenatal diagnosis regardless of age? Obstet Gynecol. 1993;81(4):615–618.
15. Chervenak FA, McCullough LB, Chervenak JL. Prenatal informed consent for sonogram: an indication for obstetric ultrasonography. Am J Obstet Gynecol. 1989;161(4):857–860.
16. Chasen ST, Skupski DW, McCullough LB, Chervenak FA. Prenatal informed consent for sonogram: the time for first-trimester nuchal translucency has come. J Ultrasound Med. 2001;20(11):1147–1152.
17. Ewigman B, LeFevre M, Bain RP, Crane JP, McNellis D. Ethics and routine ultrasonography in pregnancy. Am J Obstet Gynecol. 1990;163(1 Pt 1):256–258.
18. Wald N. First-trimester nuchal translucency screening. J Ultrasound Med. 2002;21(4):481; author reply 483–487.
19. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109(1):217–227.
20. Hewison J. Psychological aspects of individualized choice and reproductive autonomy in prenatal screening. Bioethics. 2015;29(1):9–18.
21. Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol. 2007;110(3):687–694.
22. Morain S, Greene MF, Mello MM. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369(6):499–501.
23. Simpson JL, Samango-Sprouse C. Prenatal diagnosis and 47,XXY. Am J Med Genet C Semin Med Genet. 2013;163C(1):64–70.
24. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–487.
25. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A. 2008;105(51):20458–20463.
26. Chiu RW, Sun H, Akolekar R, et al. Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. Clin Chem. 2010;56(3):459–463.
27. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A. 2008;105(42):16266–16271.
28. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(5):890–901.
29. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;207(2):137. e1–e8.
30. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011;13(11):913–920.
31. Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26–32.
32. Swanson A, Sehnert AJ, Bhatt S. Non-invasive Prenatal Testing: Technologies, Clinical Assays and Implementation Strategies for Women’s Healthcare Practitioners. Curr Genet Med Rep. 2013; 1(2):113–121.
33. Vahanian SA, Baraa Allaf M, Yeh C, Chavez MR, Kinzler WL, Vintzileos AM. Patient acceptance of non-invasive testing for fetal aneuploidy via cell-free fetal DNA. J Matern Fetal Neonatal Med. 2014;27(1):106–109.
34. Fairbrother G, Johnson S, Musci TJ, Song K. Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn. 2013;33(6):580–583.
35. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med. 2013; 15(5):395–398.
36. Lench N, Barrett A, Fielding S, et al. The clinical implementation of non-invasive prenatal diagnosis for single-gene disorders: challenges and progress made. Prenat Diagn. 2013;33(6):555–562.
37. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol. 2012;207(5):374. e1–e6.
38. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015; 372(17):1589–1597.
39. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370(9):799–808.
40. Daley R, Hill M, Chitty LS. Non-invasive prenatal diagnosis: progress and potential. Arch Dis Child Fetal Neonatal Ed. 2014; 99(5):F426–F430.
41. Hume JH, Wardrop J, Boomer T, et al. Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing. Prenat Diagn. 2015;35(10):999–1004.
42. Li R, Wan J, Zhang Y, et al. Detection of Fetal Copy Number Variations by Noninvasive Prenatal Testing for Common Aneuploidies. Ultrasound Obstet Gynecol. Epub 2015 May 29.
43. Brady P, Brison N, Van Den Bogaert K, et al. Clinical implementation of NIPT – technical and biological challenges. Clin Genet. Epub 2015 Apr 13.
44. Zhao C, Tynan J, Ehrich M, et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin Chem. 2015;61(4):608–616.
45. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 2013;42(1):15–33.
46. Davis DS. Opportunistic testing: the death of informed consent? Health Matrix Clevel. 2013;23(1):35–54.
47. de Jong A, Dondorp WJ, de Die-Smulders CE, Frints SG, de Wert GM. Non-invasive prenatal testing: ethical issues explored. Eur J Hum Genet. 2010;18(3):272–277.
48. Gekas J, Langlois S, Ravitsky V, et al. Identification of trisomy 18, trisomy 13, and Down syndrome from maternal plasma. Appl Clin Genet. 2014;7:127–131.
49. nchpeg.org [homepage on the Internet]. National Coalition for Health Professional Education in Genetics. Non-Invasive Prenatal Testing (NIPT) Factsheet. NCHPEG; 2012. Available from: http://www.nchpeg.org/index.php?option=com_content&view=article&id=384&Itemid=255. Accessed November 6, 2015.
50. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2013;33(7):622–629.
51. California Technology Assessment Forum. Fetal Aneuploidy Detection Via Maternal Plasma DNA Sequencing, part 2. CTAF; 2012. Available from: http://www.ctaf.org/assessments/fetal-aneuploidy-detection-maternal-plasma-dna-sequencing-part-2. Accessed November 6, 2015.
52. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol. 2012;120(6):1532–1534.
53. Chromosomal Abnormality using Maternal Plasma DNA. Scientific Impact Paper No15 [Internet]. 2014 [cited March 2014].
54. Langlois S, Brock JA, Wilson RD, et al. Current status in non-invasive prenatal detection of down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can. 2013;35(2):177–181.
55. BlueCross BlueShield Association. Sequencing-based tests to determine fetal down syndrome (trisomy 21) from maternal plasma DNA. Technol Eval Cent Assess Program Exec Summ. 2013;27(10):1–6.
56. Twiss P, Hill M, Daley R, Chitty LS. Non-invasive prenatal testing for Down syndrome. Semin Fetal Neonatal Med. 2014;19(1):9–14.
57. Hui L, Hyett J. Noninvasive prenatal testing for trisomy 21: challenges for implementation in Australia. Aust N Z J Obstet Gynaecol. 2013; 53(5):416–424.
58. Benn PA, Chapman AR. Practical and ethical considerations of noninvasive prenatal diagnosis. JAMA. 2009;301(20):2154–2156.
59. Chitty LS, Hill M, White H, Wright D, Morris S. Noninvasive prenatal testing for aneuploidy-ready for prime time? Am J Obstet Gynecol. 2012;206(4):269–275.
60. Ohno M, Caughey A. The role of noninvasive prenatal testing as a diagnostic versus a screening tool – a cost-effectiveness analysis. Prenat Diagn. 2013;33(7):630–635.
61. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med. 2013;26(12):1180–1185.
62. Morris S, Karlsen S, Chung N, Hill M, Chitty LS. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down’s syndrome using cell free fetal DNA in the UK National Health Service. PLoS One. 2014;9(4):e93559.
63. Fairbrother G, Burigo J, Sharon T, Song K. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. J Matern Fetal Neonatal Med. 2015:1–5.
64. Benn P, Curnow KJ, Chapman S, Michalopoulos SN, Hornberger J, Rabinowitz M. An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population. PLoS One. 2015;10(7):e0132313.
65. Walker BS, Jackson BR, LaGrave D, Ashwood ER, Schmidt RL. A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome. Prenat Diagn. 2015;35(5):440–446.
66. Walker BS, Nelson RE, Jackson BR, Grenache DG, Ashwood ER, Schmidt RL. A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States. PLoS One. 2015;10(7):e0131402.
67. Ayres AC, Whitty JA, Ellwood DA. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol. 2014;54(5):412–417.
68. Okun N, Teitelbaum M, Huang T, Dewa CS, Hoch JS. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. Prenat Diagn. 2014;34(4):350–356.
69. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. 2011;342:c7401.
70. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol. 2011;204(3):205.e1–e11.
71. Peredo EL, Les DH, King UM, Benoit LK. Extreme conservation of the psaA/psaB intercistronic spacer reveals a translational motif coincident with the evolution of land plants. J Mol Evol. 2012;75(5–6):184–197.
72. Roseman M, Milette K, Bero LA, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011;305(10):1008–1017.
73. Lumbreras B, Parker LA, Porta M, Pollan M, Ioannidis JP, Hernandez-Aguado I. Overinterpretation of clinical applicability in molecular diagnostic research. Clin Chem. 2009;55(4):786–794.
74. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699–703.
75. Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol. 2013;42(1):34–40.
76. Quezada MS, Gil MM, Francisco C, Orosz G, Nicolaides KH. Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10–11 weeks’ gestation and the combined test at 11–13 weeks. Ultrasound Obstet Gynecol. 2015;45(1):36–41.
77. Song Y, Liu C, Qi H, Zhang Y, Bian X, Liu J. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn. 2013;33(7):700–706.
78. Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn. 2010;30(1):57–64.
79. Verweij EJ, de Boer MA, Oepkes D. Non-invasive prenatal testing for trisomy 13: more harm than good? Ultrasound Obstet Gynecol. 2014;44(1):112–114.
80. Hochstenbach R, Page-Christiaens GC, van Oppen AC, et al. Unexplained False Negative Results in Noninvasive Prenatal Testing: Two Cases Involving Trisomies 13 and 18. Case Rep Genet. 2015; 2015:926545.
81. Ma J, Cram DS, Zhang J, Shang L, Yang H, Pan H. Birth of a child with trisomy 9 mosaicism syndrome associated with paternal isodisomy 9: case of a positive noninvasive prenatal test result unconfirmed by invasive prenatal diagnosis. Mol Cytogenet. 2015;8:44.
82. Lapaire O, Lu XY, Johnson KL, et al. Array-CGH analysis of cell-free fetal DNA in 10 mL of amniotic fluid supernatant. Prenat Diagn. 2007;27(7):616–621.
83. Wick JB, Johnson KJ, O’Brien J, Wick MJ. Second-trimester diagnosis of triploidy: a series of four cases. AJP Rep. 2013;3(1):37–40.
84. Samango-Sprouse C, Banjevic M, Ryan A, et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn. 2013;33(7):643–649.
85. Wang Y, Chen Y, Tian F, et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem. 2014;60(1):251–259.
86. Yao H, Jiang F, Hu H, et al. Detection of fetal sex chromosome aneuploidy by massively parallel sequencing of maternal plasma DNA: initial experience in a Chinese hospital. Ultrasound Obstet Gynecol. 2014;44(1):17–24.
87. Bianchi DW, Parsa S, Bhatt S, et al. Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstet Gynecol. 2015;125(2):375–382.
88. Chiu RW, Lo YM. Noninvasive prenatal diagnosis empowered by high-throughput sequencing. Prenat Diagn. 2012;32(4):401–406.
89. Straver R, Sistermans EA, Reinders MJ. Introducing WISECONDOR for noninvasive prenatal diagnostics. Expert Rev Mol Diagn. 2014; 14(5):513–515.
90. Benn P, Borrell A, Crossley J, et al. Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. Prenat Diagn. 2011;31(6):519–522.
91. Bianchi DW, Wilkins-Haug L. Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road? Clin Chem. 2014;60(1):78–87.
92. Taglauer ES, Wilkins-Haug L, Bianchi DW. Review: cell-free fetal DNA in the maternal circulation as an indication of placental health and disease. Placenta. 2014;35 Suppl:S64–S68.
93. Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. JAMA. 2015;314(2):162–169.
94. Ledbetter DH, Zachary JM, Simpson JL, et al. Cytogenetic results from the US Collaborative Study on CVS. Prenat Diagn. 1992;12(5):317–345.
95. Stetten G, Escallon CS, South ST, McMichael JL, Saul DO, Blakemore KJ. Reevaluating confined placental mosaicism. Am J Med Genet A. 2004;131(3):232–239.
96. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn. 2012;32(1):3–9.
97. Artan S, Basaran N, Hassa H, et al. Confined placental mosaicism in term placentae: analysis of 125 cases. Prenat Diagn. 1995; 15(12):1135–1142.
98. Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med. 2012;14(3):296–305.
99. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn. 2013;33(7):667–674.
100. Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33(7):662–666.
101. Huang X, Zheng J, Chen M, et al. Noninvasive prenatal testing of trisomies 21 and 18 by massively parallel sequencing of maternal plasma DNA in twin pregnancies. Prenat Diagn. 2014;34(4):335–340.
102. Hill M, Wright D, Daley R, et al. Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol. BMC Pregnancy Childbirth. 2014;14:229.
103. Cuckle H, Benn P, Pergament E. Cell-free DNA screening for fetal aneuploidy as a clinical service. Clin Biochem. 2015;48(15):932–941.
104. Salomon LJ, Alfirevic Z, Audibert F, et al. ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound Obstet Gynecol. 2014;44(1):122–123.
105. Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH. Maternal plasma cell-free fetal and maternal DNA at 11–13 weeks’ gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther. 2013;33(4):215–223.
106. Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med. 2012;18(7):1041–1051.
107. Jorgensen JM, Hedley PL, Gjerris M, Christiansen M. Including ethical considerations in models for first-trimester screening for pre-eclampsia. Reprod Biomed Online. 2014;28(5):638–643.
108. de Jong A, de Wert GM. Prenatal screening: an ethical agenda for the near future. Bioethics. 2015;29(1):46–55.
109. Petersen OB, Vogel I, Ekelund C, et al. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. Ultrasound Obstet Gynecol. 2014;43(3):265–271.
110. Deans Z, Newson AJ. Ethical considerations for choosing between possible models for using NIPD for aneuploidy detection. J Med Ethics. 2012;38(10):614–618.
111. Tischler R, Hudgins L, Blumenfeld YJ, Greely HT, Ormond KE. Noninvasive prenatal diagnosis: pregnant women’s interest and expected uptake. Prenat Diagn. 2011;31(13):1292–1299.
112. Schmitz D, Henn W, Netzer C. Commentary: No risk, no objections? Ethical pitfalls of cell-free fetal DNA and RNA testing. BMJ. 2009; 339:b2690.
113. Wilson JM, Jungner YG. Principios y práctica de cribado de la población. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968;65(4):281–393. Spanish.
114. Newson AJ. Ethical aspects arising from non-invasive fetal diagnosis. Semin Fetal Neonatal Med. 2008;13(2):103–108.
115. Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2013;42(1):41–50.
116. ComitéConsultatif National d’Ethique pour les sciences de la vie et de la santé(France). Questions éthiques associées au développement des tests génétiques foetaux sur sang maternel. [Ethical issues associated with the development of fetal genetic testing from maternal blood]. Available from: http://www.ccne-ethique.fr/sites/default/files/publications/avis-120.pdf. Accessed June 22th, 2015. French.
117. Lewis C, Silcock C, Chitty LS. Non-invasive prenatal testing for Down’s syndrome: pregnant women’s views and likely uptake. Public Health Genomics. 2013;16(5):223–232.
118. van Schendel RV, Kleinveld JH, Dondorp WJ, et al. Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. Eur J Hum Genet. 2014;22(12):1345–1350.
119. bzga.de [homepage on the Internet]. Renner I. Experience of Pregnancy and Prenatal Diagnosis 2006. Available from: http://www.bzga.de/?uid=25d093aacb9296ea646b087b68c27996&id=medien&sid=88&idx=1496. Accessed November 6, 2015.
120. Favre R, Duchange N, Vayssiere C, et al. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study. Prenat Diagn. 2007;27(3):197–205.
121. Seavilleklein V. Challenging the rhetoric of choice in prenatal screening. Bioethics. 2009;23(1):68–77.
122. van den Heuvel A, Chitty L, Dormandy E, et al. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. Patient Educ Couns. 2010;78(1):24–28.
123. Chervenak FA, McCullough LB, Sharma G, Davis J, Gross S. Enhancing patient autonomy with risk assessment and invasive diagnosis: an ethical solution to a clinical challenge. Am J Obstet Gynecol. 2008;199(1):19. e1–e4.
124. Agarwal A, Sayres LC, Cho MK, Cook-Deegan R, Chandrasekharan S. Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn. 2013;33(6):521–531.
125. Kooij L, Tymstra T, Berg P. The attitude of women toward current and future possibilities of diagnostic testing in maternal blood using fetal DNA. Prenat Diagn. 2009;29(2):164–168.
126. Greely HT. Get ready for the flood of fetal gene screening. Nature. 2011;469(7330):289–291.
127. Ravitsky V. Non-invasive prenatal diagnosis: an ethical imperative. Nat Rev Genet. 2009;10(10):733.
128. Ames AG, Metcalfe SA, Dalton Archibald A, Duncan RE, Emery J. Measuring informed choice in population-based reproductive genetic screening: a systematic review. Eur J Hum Genet. 2015;23(1):8–21.
129. van Agt HM, Korfage IJ, Essink-Bot ML. Interventions to enhance informed choices among invitees of screening programmes-a systematic review. Eur J Public Health. 2014;24(5):789–801.
130. Hippman C, Inglis A, Austin J. What is a “balanced” description? Insight from parents of individuals with down syndrome. J Genet Couns. 2012;21(1):35–44.
131. Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns. 2013;22(3):291–295.
132. Chachkin CJ. What potent blood: non-invasive prenatal genetic diagnosis and the transformation of modern prenatal care. Am J Law Med. 2007;33(1):9–53.
133. Hall A, Bostanci A, Wright CF. Non-invasive prenatal diagnosis using cell-free fetal DNA technology: applications and implications. Public Health Genomics. 2010;13(4):246–255.
134. Deans Z, Clarke AJ, Newson AJ. For your interest? The ethical acceptability of using non-invasive prenatal testing to test ‘purely for information’. Bioethics. 2015;29(1):19–25.
135. Skirton H, Patch C. Factors affecting the clinical use of non-invasive prenatal testing: a mixed methods systematic review. Prenat Diagn. 2013;33(6):532–541.
136. Hill M, Lewis C, Jenkins L, Allen S, Elles RG, Chitty LS. Implementing noninvasive prenatal fetal sex determination using cell-free fetal DNA in the United Kingdom. Expert Opin Biol Ther. 2012;12 Suppl 1:S119–S126.
137. George SM. Millions of missing girls: from fetal sexing to high technology sex selection in India. Prenat Diagn. 2006;26(7):604–609.
138. Lai-wan CC, Blyth E, Hoi-yan CC. Attitudes to and practices regarding sex selection in China. Prenat Diagn. 2006;26(7):610–613.
139. Madan K, Breuning MH. Impact of prenatal technologies on the sex ratio in India: an overview. Genet Med. 2014;16(6):425–432.
140. Dondorp W, De Wert G, Pennings G, et al. ESHRE Task Force on ethics and Law 20: sex selection for non-medical reasons. Hum Reprod. 2013;28(6):1448–1454.
141. Kitzman JO, Snyder MW, Ventura M, et al. Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med. 2012;4(137):137ra76.
142. Farrimond HR, Kelly SE. Public viewpoints on new non-invasive prenatal genetic tests. Public Underst Sci. 2013;22(6):730–744.
143. van El CG, Cornel MC, Borry P, et al. Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2013;21 Suppl 1:S1–S5.
144. Committee On Bioethics; Committee On Genetics and, American College Of Medical Genetics and, Genomics S, Ethical, Legal Issues C. Ethical and policy issues in genetic testing and screening of children. Pediatrics. 2013;131(3):620–622.
145. Warsof SL, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn. 2015;35(10):972–979.
146. Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. Prenat Diagn. 2015; 35(10):959–967.
147. Williams J 3rd, Rad S, Beauchamp S, et al. Utilization of noninvasive prenatal testing: impact on referrals for diagnostic testing. Am J Obstet Gynecol. 2015;213(1):102. e1–e6.
148. Munthe C. A new ethical landscape of prenatal testing: individualizing choice to serve autonomy and promote public health: a radical proposal. Bioethics. 2015;29(1):36–45.
149. Hui L, Teoh M, Piessens S, Walker SP. Early clinical experience of cell-free DNA-based aneuploidy screening: A survey of obstetric sonologists in Australia and New Zealand. Aust N Z J Obstet Gynaecol. 2015;55(2):138–143.
150. Norton ME, Rose NC, Benn P. Noninvasive prenatal testing for fetal aneuploidy: clinical assessment and a plea for restraint. Obstet Gynecol. 2013;121(4):847–850.
151. wsj.com [homepage on the Internet]. Weaver C. Tough calls on prenatal tests. Wall Street Journal; 2013. Available from: http://www.wsj.com/articles/SB10001424127887324883604578398791568615644. Accessed November 6, 2015.
152. Ioannidis JP. Biomarker failures. Clin Chem. 2013;59(1):202–204.
153. Dyer O. The challenge of doing less. BMJ. 2013;347:f5904.
154. Technologies de la santé et prise de décision. [Health technologies and decision making]. Organisation for Economic Co-operation and Development. In: Health Technologies and Decision Making. Paris: OECD Publishing; 2005:158. French.
155. Beulen L, Grutters JP, Faas BH, Feenstra I, van Vugt JM, Bekker MN. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:53–61.
156. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis. Prenat Diagn. 2013; 33(7):636–642.
157. Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open. 2014;4(11):e005922.
158. Manegold-Brauer G, Berg C, Flock A, Ruland A, Gembruch U, Geipel A. Uptake of non-invasive prenatal testing (NIPT) and impact on invasive procedures in a tertiary referral center. Arch Gynecol Obstet. 2015;292(3):543–548.
159. Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ. Association of combined first-trimester screen and noninvasive prenatal testing on diagnostic procedures. Obstet Gynecol. 2014; 123(6):1303–1310.
160. Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med. 2012;367(23):2175–2184.
161. Hayden EC. Prenatal-screening companies expand scope of DNA tests. Nature. 2014;507(7490):19.
162. Lau TK, Jiang FM, Stevenson RJ, et al. Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service. Prenat Diagn. 2013; 33(6):602–608.
163. Mazloom AR, Dzakula Z, Oeth P, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn. 2013;33(6):591–597.
164. Vora NL, O’Brien BM. Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies: proceed with caution. Obstet Gynecol. 2014;123(5):1097–1099.
165. Crawford G, Foulds N, Fenwick A, Hallowell N, Lucassen A. Genetic medicine and incidental findings: it is more complicated than deciding whether to disclose or not. Genet Med. 2013;15(11):896–869.
166. Lo KK, Boustred C, Chitty LS, Plagnol V. RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy. Bioinformatics. 2014;30(20):2965–2967